Triptorelin Research: What 2,494 Studies Show (2026) | RetatrutideCompare

Triptorelin — 2,494 studies indexed on PubMed. GnRH super-agonist with desensitization profile similar to Leuprolide. Half-life: ~3 hours (depot formulations). FDA status: FDA-approved (2000).

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Triptorelin?

There are approximately 2,494 studies indexed on PubMed that mention Triptorelin (Trelstar, Decapeptyl), based on a search last updated 2026-06-18.

Is Triptorelin FDA-approved?

FDA status: FDA-approved (2000).

How does Triptorelin work?

GnRH super-agonist with desensitization profile similar to Leuprolide.

Reference facts

Also known as: Trelstar, Decapeptyl
Category: GnRH & Reproductive
Mechanism of action: GnRH super-agonist with desensitization profile similar to Leuprolide.
Targets: GnRH receptor
Indications under research or approved: Advanced prostate cancer, Central precocious puberty
Regulatory status (reference entry): FDA-approved (2000)
Half-life: ~3 hours (depot formulations)
Sequence notes: Decapeptide pyroGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2; D-Trp at position 6 confers super-agonist activity.
Molecular weight (Da): 1311
Originator / sponsor: Verity Pharmaceuticals / Ipsen
First reported: 1980

Primary References

Trelstar FDA label

Explore research articles about Triptorelin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.